FDA reviewers question IDegLira's superiority to Tresiba

In Novo Nordisk A/S (CSE:NVO; NYSE:NVO) had shown its Type II diabetes combination therapy IDegLira insulin degludec/liraglutide is superior to Tresiba insulin degludec alone. The agency's FDA's Endocrinologic and Metabolic Drugs Advisory Committee is to discuss an NDA for IDegLira, which Novo markets in

Read the full 448 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE